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ThailandA B S T R A C TObjective: This study aimed to evaluate the cost-utility of the home-
based care policy versus the no home-based care policy of factor VIII
and factor IX concentrate in Thai patients with hemophilia A and B
who had no inhibitor or less than 5 Bethesda units. Methods: A
Markov model was used to evaluate the cost utility of the two policies.
The ﬁrst policy was “no home-based care” in which patients were
treated with blood components only when admitted at the hospital but
without home treatment. The second policy was “home-based care” in
which factors were prescribed and infused for treatment of early
bleeding episodes at home. Input parameters related to clinical and
cost were obtained from primary data collection at the National Health
Security Ofﬁce, while patients’ quality of life was surveyed frommailed
questionnaires. Both costs and health outcomes were discounted at 3%.
One-way analysis and probabilistic sensitivity analysis were performedee front matter Copyright & 2014, International S
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yathai, Bangkok 10400, Thailand.to assess uncertainty surrounding model parameters. Results: Based
on governmental perspective, the “home-based care” policy had cost
saving in patients with moderate and severe hemophilia when com-
pared with the “no home-based care” policy; in patients with mild
hemophilia, the incremental cost-effectiveness ratio was 80,542 Thai-
land baht (THB) or US $2,684.73 (US $1 ¼ 30 THB). Conclusions: At the
ceiling threshold of one time of gross domestic product per capita
(120,000 THB per quality-adjusted life-year gained), the “home-based
care” policy was cost-effective when compared with the “no home-
based care” policy.
Keywords: cost-utility, factor VIII concentrate, factor IX concentrate,
hemophilia A, hemophilia B.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hemophilia A and B are hereditary X-linked disorders caused by a
deﬁciency of clotting factor VIII and IX in the blood [1,2]. The
disease can be deﬁned as mild, moderate, or severe depending on
the degree of deﬁciency of the factor. Patients with hemophilia
require lifelong replacement therapy to control bleeding episodes,
with impact on their quality of life. Hemophilia, however, is not
given the priority it deserves in economically less-developed
countries because there is a high number of other serious health
problems. The replacement therapy is mainly limited to locally
prepared fresh frozen plasma, cryoprecipitate, and cryo-removed
plasma, which are not virus-inactivated products. Patients risk
contracting transfusion-transmitted diseases. The virus-inactivated
factor concentrate is seldom used because of the high price.
Impressively, the established home-based care for 85 patients with
hemophilia at the International Hemophilia Training Center-Bang-
kok, with limited resources, has signiﬁcantly decreased the risk of
death and increased the survival time [3]. Home care treatment can
be adopted even by parents with low literacy.
Factor VIII and factor IX concentrate have been listed in the
National Drug List, an essential drug, since 2008 to supportpatients on home treatment under the Universal Coverage
Scheme [4]. The mean per capita factor VIII use in Thailand in
2010, however, was 0.077 IU per year, compared with the global
use at 1.433 IU per year [5]. In 2012, only 1171 or one fourth of
estimated patients with hemophilia in Thailand were registered
and able to access the medicines. No study, however, has been
conducted in Thailand considering cost utility of home-based
care treatment. This study was conducted to evaluate the cost
utility of the home-based care policy versus the no home-based
care policy of factor VIII and factor IX concentrate in Thai
patients with hemophilia A and B who had no inhibitor or less
than 5 Bethesda units (BU).Methods
Our study conducted a cost-utility analysis, an economic evalua-
tion that estimates the cost per quality-adjusted life-year (QALY),
and was designed to comply with Thai Health Technology
Assessment Process Guidelines [6]. The Markov model was used
to analyze the cost utility of the two treatment policies: providingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – The health states included in the Markov model.
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episodes at home from the perspective of the Thai government.
The Markov model is a decision-analytical model used to
estimate the cost-effectiveness of health care interventions. It is
particularly suited to modeling chronic disease [7]. In a Markov
model, a patient’s possible prognosis is divided into distinct
health states. Costs and beneﬁts are assigned to each health
state and move over a cycle until the last cycle is reached. The
costs and beneﬁts of comparative interventions are then esti-
mated according to the time spent in each state.
The health states included in the Markov model are shown in
Fig. 1. The ovals represent the possible health states, and the
arrows indicate the possible transition between those states. Life-
threatening bleeding is deﬁned as hemorrhage or bleeding lead-
ing to death, requiring prompt hospital intervention, whereas
emergency surgery is a surgical procedure that risks bleeding;
thus, prevention of bleeding in the operation room is requested.
With a 1-year cycle length, the model was structured with the
following assumptions:1.T
F
W
L
E
P
NAll individuals entered the model in the health state “well.”
2. At the following cycle, individuals remained in the health
state well or entered the health states “life threatening” or
“emergency surgery” or “death.”3. In each cycle, individuals in the life-threatening state may
also receive emergency surgery and individuals in the emer-
gency surgery state may also be in the life-threatening state.
After the treatment, individuals can pass to the well state or
death at the end of the cycle.
The cycle will run until the individual reaches the age of 99
years or is dead. Our model was run for a hypothetical cohort ofable 1 – 1-y transition probability matrix.
rom state:
Well L
ell 1 (Probdeath þ ProbLT þ ProbES)
ife threatening 1  ProbLT P
mergency surgery 1  ProbES
robdeath, probability of death; ProbES, probability of requiring emergency
ote: All row probabilities sum to 1.5000 Thai patients with hemophilia A and B who had no inhibitor
or less than 5 BU, with the severity proportion of severe:
moderate:mild patients at 40:38:22 [8]. Patients’ severity was
considered by level of clotting factor activity. Patients with less
than 1% were classiﬁed as having severe hemophilia, those with
1% to 5% and more than 5% to 40% had moderate and mild
hemophilia, respectively. The model was run to simulate two
scenarios. Scenario 1 was for “no home-based care” in which
patients were treated with blood components only when admit-
ted at the hospital but no home treatment. Scenario 2 was for
“home-based care” in which factors were prescribed and infused
by patients for treatment of early bleeding episodes at home.Transition Probabilities
The 1-year transition probability matrix is shown in Table 1.
Probability of death (Table 2) was estimated from a life table for
Thai population by age group [9] adjusted by available evidence of
mortality rate in people with hemophilia A or B but without HIV
infection in the United Kingdom [10]. Data of annual probability
of requiring emergency surgery and life-threatening operation
(Table 3) were obtained from registered patients under the
National Health Security Ofﬁce (NHSO). The data were collected
from electronic databases from 29 hospitals in 21 provinces in
2007 (n ¼ 328) [11] and from drug reimbursement data between
2007 and 2012 submitted to the NHSO (n ¼ 563) [8].Resource Use
Lifetime cost of treatment in this study was considered as factor
concentrate provided for early treatment of bleeding episodes at
home for the home-based care policy and treatment cost at
hospitals for emergency surgery and life-threatening operation.
Treatment cost at hospital comprised the cost of factor concen-
trate and other medications used, such as blood components,
medicines, and medical supplies, and cost for laboratory tests,
room, doctor fee, and so forth. The calculation is as follows:
Direct medical cost ¼ cost of factor concentrate provided at
home per year þ
[(rate of emergency surgery per year)  (length of stay per
emergency surgery)  (cost of factor concentrate per day þ cost of
other medical use per day)] þ
[(rate of life-threatening operation per year)  (length of stay
per life-threatening operation)  (cost of factor concentrate per
day þ cost of other medical use per day)]Cost of factor concentrate
Cost of factor concentrate used in the model was obtained from
the Food and Drug Administration price quotation, which was
3424 and 6848 Thailand baht (THB) per vial, for 250 and 500 IU,
respectively.To state:
ife threatening Emergency surgery Death
ProbLT ProbES Probdeath
robLT  Probdeath 0 Probdeath
0 ProbES  Probdeath Probdeath
surgery; ProbLT, probability of requiring life-threatening operation.
Table 2 – Probability of death.
Age group (y) Death rate per year Probability of death per year*
Mild to moderate Severe Mild to moderate Severe
0–4 0.00254 0.00647 0.00253 0.00644
5–9 0.00261 0.00365 0.00261 0.00365
10–14 0.00233 0.00327 0.00233 0.00326
15–19 0.00179 0.00423 0.00179 0.00422
20–24 0.00258 0.00474 0.00200 0.00473
25–29 0.00345 0.00882 0.00258 0.00878
30–34 0.00336 0.01176 0.00344 0.01169
35–39 0.00427 0.01345 0.00336 0.01336
40–44 0.00650 0.01706 0.00426 0.01692
45–49 0.00880 0.01995 0.00648 0.01975
50–54 0.01237 0.02700 0.00876 0.02664
55–59 0.01834 0.03149 0.01229 0.03100
60–64 0.02680 0.04668 0.01817 0.04561
65–69 0.04397 0.04157 0.02644 0.04071
70–74 0.05916 0.06820 0.04301 0.06592
75–79 0.09351 0.08580 0.05744 0.08222
80–84 0.09351 0.13562 0.08927 0.12683
85þ 0.14040 0.20363 0.13099 0.18424
* Probability of death per year ¼ 1  exp(death rate per year  time).
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All other medical costs and patients’ length of stay (LOS) were
obtained from data of registered patients under the NHSO
(Tables 4–6). Resource use was considered by patient’s age. A
child was deﬁned as an individual younger than 10 years,
whereas an adult was deﬁned as an individual 10 years or older.Utility
Because of the lack of utility data on health-related quality of life
of Thai individuals with hemophilia A and B, the study, with the
Ethics Committee approval from Ramathibodi Hospital, surveyed
the quality of life of 105 Thai patients by mailed questionnaires.
The response rate was 54.28% or 57 cases. The questionnaire had
three parts: ﬁrst was patient’s demographic characteristics.Table 3 – Transition probabilities used in the model.
Transition
probabilities
Distribution Mean  SD
No home-
based care
Home-
based care
Rate of emergency surgery per year (times)
Child mild Gamma 1.1  0.9 0.7  1.2
Child moderate Gamma 1.1  1.0 1.4  0.8
Child severe Gamma 3.1  3.1 2.1  1.9
Adult mild Gamma 1.4  1.5 1.0  1.3
Adult moderate Gamma 1.5  2.1 0.7  1.1
Adult severe Gamma 3.3  3.6 2.1  2.4
Rate of life-threatening operation per year (times)
Child mild Gamma 0.1  0.1 0.1  0.1
Child moderate Gamma 1.0  0.9 1.3  0.8
Child severe Gamma 2.0  2.0 1.3  1.2
Adult mild Gamma 0.3  0.4 0.2  0.3
Adult moderate Gamma 0.8  1.1 0.4  0.6
Adult severe Gamma 1.2  1.3 0.8  0.9Second and third parts were the visual analogue scale before
and after attending home-based care, respectively. The visual
analogue scale was scored between 0 and 1, where 0 meant dead
and 1 meant perfect life. Utility was then calculated as QALY ¼
quality of life  life-year saved (Table 7).Cost-Utility Analysis
Cost utility of the two policies for each severity level was
calculated as cost per QALY by using the following equation:
Lifetime cost of treatment/Utility (QALY).
In addition, to compare cost and utility between the policies,
incremental cost-effectiveness ratio (ICER) was calculated as
follows:Table 4 – Resources use (length of stay: LOS) used in
the model.
Resources use Distribution Mean  SD
No home-
based care
Home-
based care
LOS per emergency surgery (d)
Child mild Normal 7.6  0.6 5.0  0.5
Child moderate Normal 9.7  1.1 8.1  0.6
Child severe Normal 23.3  2.3 6.9  0.8
Adult mild Normal 6.9  0.8 6.9  1.0
Adult moderate Normal 10.7  1.5 8.1  0.9
Adult severe Normal 18.7  1.9 5.9  0.6
LOS per life-threatening operation (d)
Child mild Normal 3.0  0.3 3.0  0.3
Child moderate Normal 13.0  1.0 13.0  1.0
Child severe Normal 12.9  1.1 12.9  1.1
Adult mild Normal 7.7  0.7 7.7  0.7
Adult moderate Normal 9.3  1.2 9.3  1.2
Adult severe Normal 8.3  1.0 8.3  1.0
LOS, length of stay.
Table 5 – Cost of factor concentrate.
Cost Distribution Mean  SD
No home-based care Home-based care
Cost of factor concentrate at home (THB)
Child mild Normal –  – 36,000  3,600
Child moderate Normal –  – 90,000  9,000
Child severe Normal –  – 120,000  12,000
Adult mild Normal –  – 72,000  7,200
Adult moderate Normal –  – 144,000  14,400
Adult severe Normal –  – 144,000  14,400
Cost of factor concentrate per day for emergency surgery (THB)
Child mild Normal 2,151.6  382.7 2,151.6  382.7
Child moderate Normal 4,841.1  644.0 4,841.1  644.0
Child severe Normal 12,124.1  2,608.2 12,124.1  2,608.2
Adult mild Normal 13,718.7  2,354.6 13,718.7  2,354.6
Adult moderate Normal 20,563.9  3,691.2 20,563.9  3,691.2
Adult severe Normal 21,552.4  3,914.0 21,552.4  3,914.0
Cost of factor concentrate per day for life-threatening operation (THB)
Child mild Normal –  – –  –
Child moderate Normal 6,248.6  503.5 6,248.6  503.5
Child severe Normal 14,507.8  3,476.0 14,507.8  3,476.0
Adult mild Normal 2,401.1  415.5 2,401.1  415.5
Adult moderate Normal 25,428.1  3,960.1 25,428.1  3,960.1
Adult severe Normal 45,868.0  6,774.1 45,868.0  6,774.1
THB, Thailand baht.
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Utility of no home-based care)
All costs used in the study are in THB. Cost and utility values
were adjusted to base year at 2012 with a 3% discount rate.
Sensitivity Analysis
One-way sensitivity analysis was performed for children with
mild hemophilia, varying the discount rate (0%–6%), rate of
hospitalization (95% conﬁdence interval), LOS (95% conﬁdence
interval), and cost of factor concentrate (10%). In addition,
probabilistic sensitivity analysis was simulated by using the
Monte-Carlo method. Using Microsoft Excel, the number was
sampled 5000 times according to each parameter’s distribution.Results
The analysis showed that, on governmental perspective,
expected lifetime costs of treating Thai patients with hemophiliaTable 6 – Other direct medical cost.
Cost Distribution Mean  SD
No home-
based care
Home-
based care
Other direct medical cost per day (THB)
Child mild Gamma 5432.3  2349.4 5105.0  2015.3
Child moderate Gamma 4747.4  1635.6 4437.7  1408.3
Child severe Gamma 4747.9  2724.2 4960.7  2409.4
Adult mild Gamma 5246.1  2596.8 4811.4  1650.0
Adult moderate Gamma 5006.5  2408.2 5249.8  2688.0
Adult severe Gamma 6614.2  2992.3 6062.0  3333.5
THB, Thailand baht.A or B who had no inhibitor or less than 5 BU were 5.22 (for
mild), 11.20 (for moderate), and 20.19 (for severe) million THB in
case of providing factor concentrate for treating early bleeding
episodes at home and were 5.00 (for mild), 13.66 (for moderate),
and 25.91 (for severe) million THB in case of not providing factor
concentrate at home (Table 8). The associated QALYs were
approximately 23.29 (for mild), 16.47 (for moderate), and 12.21
(for severe) in cases of no home-based care and 26.11 (for
mild), 22.44 (for moderate), and 20.61 (for severe) in cases of
home-based care.
The cost and utility given above produced a cost per QALY of
214,595 (for mild), 829,504 (for moderate), and 2,122,085 (for
severe) THB in the no home-based care scenario and 200,103
(for mild), 499,157 (for moderate), and 979,557 (for severe) THB in
the home-based care scenario. When comparing the two policies,
an ICER was cost saving in moderate and severe cases and 80,542
THB per QALY gain in mild cases.
From one-way sensitivity analysis, in mild hemophilia,
results were most sensitive to the rate of hospitalization
(Fig. 2) followed by LOS, cost of factor concentrate, and discount
rate, respectively.
With probabilistic sensitivity analysis, the home-based care
policy was found to be more cost-effective than the no home-
based care policy in any value of ceiling ratio (Fig 3).Table 7 – Utility used in the model.
Severity Distribution Mean  SD
No home-
based care
Home-based
care
Mild Beta 0.8250  0.1250 0.9250  0.0829
Moderate Beta 0.5833  0.0850 0.7947  0.1495
Severe Beta 0.4833  0.0687 0.8159  0.1433
Table 8 – Lifetime cost of treatment, quality-adjusted life-year (QALY), and incremental cost-effectiveness
ratios (ICERs) for patient with and without home-based care.
Severity Policy Lifetime cost of treatment (THB) QALY Cost per QALY ICER
Mild No home-based care 4,998,017 23.29 214,595
Home-based care 5,225,394 26.11 200,103 80,542
Moderate No home-based care 13,659,490 16.47 829,504
Home-based care 11,198,618 22.44 499,157 Cost saving
Severe No home-based care 25,908,099 12.21 2,122,085
Home-based care 20,189,367 20.61 979,557 Cost saving
Rate of hospitalization
(95% CI)
Length of stay
(95% CI)
Cost of factor concentrate
(+10%, -10%)
Discount rate
(6%, 0%)
Reference case (mild hemophilia) ICER 80,542 bath per QALY
150,000 300,000 450,000 600,000-600,000 -450,000 -300,000 -150,000 -
-14.4%
-570.1%
-46.1%
15.9%
46.1%
719.5%
196.3%-195.9%
Fig. 2 – One-way sensitivity analysis. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Fig. 3 – Probabilistic sensitivity analysis. THB, Thai Baht.
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This study was conducted to assess the cost utility of providing
versus not providing factor concentrate to treat patients with
hemophilia A or B who had no inhibitor or less than 5 BU at
home. The Markov model used data from different sources.
The analysis showed that cost per QALY of patients without
home-based care was 214,595 to 2,122,085 THB and that of
patients with home-based care was 200,103 to 979,557 THB. When
comparing the two policies, an ICER was cost saving in moderate
and severe cases and 80,542 THB per QALY gain in mild cases. In
all patient groups, less than one time of gross domestic product
per capita (120,000 THB per QALY gained) was found.
Compared with other Thai studies, in 2009, Suksriwong et al.
[12] came up with the economics clinical and humanistic out-
comes model, which was not a full economic evaluation to assess
cost and utility of patients with hemophilia registered under the
NHSO. After providing patients factor concentrate for treatment
of early bleedings episodes at home, the number of patients
needing hospitalization decreased from 5.19 to 2.65 times per
year. In terms of utility, 77.9% of the patients said their life and
family were better.
A number of economic evaluations of prophylaxis with factor
concentrate were reported in other countries, mostly in patients
with severe hemophilia. In 2002, Miners et al. [13] assessed the
cost-effectiveness of primary prophylaxis with clotting factor
instead of treatment following a bleeding episode for UK individ-
uals with severe hemophilia using the Markov model in the
societal perspective. The results showed that an additional
£46,500 and £8,600 per QALY gained was needed for severe
hemophilia A and B, respectively. In 2009, Miners [14] revisited
the assessment to estimate the value of conducting research to
reduce the parameter uncertainties and found that the ICER for
patients with hemophilia A was approximately £37,000 (£10,000
lower than the value published in 2002).
Another full economics evaluation, in Italy, evaluated the
cost-effectiveness of primary prophylaxis with factor VIII con-
centrates versus treatment following a bleeding episode in
patients with severe hemophilia A in 2011. With the lifetime
Markov model, the result showed that incremental cost per QALY
gained was €40,229 [15].
The results of our and other analysis revealed that prophy-
laxis in patients with severe hemophilia A is a cost-effective
strategy compared with treatment following a bleeding episode,
as demonstrated by the QALY values obtained.
Our model has a number of limitations mainly due to the
assumptions made and the data used, some of which were derived
from different sources. The possible direct nonmedical and indirect
costs, such as traveling cost and caregiver and patient’s produc-
tivity loss, were not considered in this study. Another important
limitation is the assumptions on which the analysis was based to
simplify the model or in case of incomplete data. Speciﬁcally, this
regarded the death rate, derived from Thai population by age groupand an available evidence of mortality rate in people with hemo-
philia A or B but without HIV in the United Kingdom.Conclusions
In Thailand, it is cost saving to provide factor concentrate to
patients with moderate and severe hemophilia A or B to treat
their early bleeding episodes at home. In addition, it is also cost-
effective for mild hemophilia cases, with the ceiling threshold of
one time of gross domestic product per capita (120,000 THB per
QALY gained). The government should continue supporting
“home-based care” programs originated by the NHSO and expand
the coverage to all patients with hemophilia.
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